Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
54.4M
-
Shares change
-
+3.04M
-
Total reported value, excl. options
-
$374M
-
Value change
-
+$23.5M
-
Put/Call ratio
-
0.11
-
Number of buys
-
58
-
Number of sells
-
-64
-
Price
-
$6.88
Significant Holders of Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) as of Q2 2025
149 filings reported holding FULC - Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.4M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10.2M shares), TCG Crossover Management, LLC (5.25M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (5.08M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.59M shares), BlackRock, Inc. (4.38M shares), Nantahala Capital Management, LLC (4.29M shares), VANGUARD GROUP INC (3.15M shares), DIMENSIONAL FUND ADVISORS LP (1.37M shares), Balyasny Asset Management L.P. (1.34M shares), and STATE STREET CORP (1.22M shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.